17 recruiting, 15 active not recruiting, 9 not yet recruiting, 7 completed. 34 Phase 2, 20 Phase 1, 2 Early Phase 1, 2 Not applicable.
Follow Turcot syndrome: new trials by email Literature Review of Turcot syndrome trials Research Report on Turcot syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of DES-1357 in People With Deficient Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer (mCRC) DES-1357 - Metastatic Colorectal Cancer (CRC) | Phase 1 / Phase 2 | Not yet recruiting | D. E. Shaw Research, LLC | 88 | 2026-12-03 | 2026-09-08 |
| Study Aiming to Test Whether Non-invasive Liquid Biopsies Can Safely Reduce Invasive Surveillance Methods in Lynch Syndrome INVITRO DIAGNOSTIC TESTS AND COLONOSCOPY - Lynch Syndrome | Not applicable | Not yet recruiting | UNICANCER | 2000 | 2026-12-01 | 2026-08-03 |
| MMR Status Modulates the Predictive Value of Lymphatic Invasion for Lymph Node Metastasis in Gastrointestinal Cancers Mismatch repair (MMR) status, Lymphatic invasion status - Gastric / Gastroesophageal Junction Adenocarcinoma, Mismatch Repair Deficient or MSI-High Solid Tumors | Not yet recruiting | Shanghai Zhongshan Hospital | 5000 | 2026-11-01 | 2026-10-27 | |
| ABCSG R07 Rectal Cancer Registry Rectal Cancer, Adenocarcinoma of Rectum | Recruiting | Austrian Breast & Colorectal Cancer Study Group | 600 | 2026-09-16 | 2026-10-30 | |
| Research on Effective Strategies After Immunotherapy for Mismatch Repair-deficient Early-stage GI Tumors Active surveillance after complete response to immunotherapy in MMRd GI cancers, Stand of Care - Quality of Life (QOL), Mismatch Repair Deficient Colorectal Cancer | Recruiting | University Hospital, Basel, Switzerland | 234 | 2026-09-01 | 2026-09-18 | |
| Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency Pembrolizumab, Navifus Focused Ultrasound Sonification - Glioblastoma, Mismatch Repair Deficiency | Phase 1 | Not yet recruiting | Jennifer Leddon | 8 | 2026-06-01 | 2026-02-04 |
| Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial Cancer Iparomlimab and Tuvonralimab (QL1706) - Endometrial Cancer, Immunotherapy | Phase 2 | Not yet recruiting | Women's Hospital School Of Medicine Zhejiang University | 30 | 2026-03-01 | 2026-01-27 |
| Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer Nivolumab, Ipilimumab (1mg/kg), PULSAR - Colorectal Cancer (MSI-H) | Phase 2 | Not yet recruiting | Fudan University | 114 | 2026-02-01 | 2026-02-11 |
| Factors Influencing Immunotherapy Response in dMMR/MSI-H Gastric/Gastroesophageal Junction Adenocarcinoma Immunotherapy, Induction chemotherapy, D2 radical gastrectomy - Gastric / Gastroesophageal Junction Adenocarcinoma, Mismatch Repair Deficient or MSI-High Solid Tumors | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 15 | 2026-01-31 | 2026-01-07 |
| Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma：A Randomized, Non-comparative Phase 2 Study Adebrelimab, XELOX, SHR-8068 - Gastric Adenocarcinoma, Gastroesophageal Adenocarcinoma | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 30 | 2026-01-30 | 2026-01-27 |
| EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors EIK1005, pembrolizumab (KEYTRUDA® ) - Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors | Phase 1 / Phase 2 | Recruiting | Eikon Therapeutics | 160 | 2026-01-20 | 2026-10-30 |
| A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors GSK5460025 - Neoplasms, Colorectal, Neoplasms | Phase 1 / Phase 2 | Recruiting | GlaxoSmithKline | 47 | 2025-10-20 | 2026-09-16 |
| Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: PREMICES Study. Pembrolizumab Injection [Keytruda], Watch-and-wait approach, Surgery - Colon Cancer | Phase 2 | Not yet recruiting | GERCOR - Multidisciplinary Oncology Cooperative Group | 60 | 2025-09-01 | 2025-06-13 |
| Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer Toripalimab plus celecoxib, Non-operative management, Curative-intent surgery - Colorectal Cancer, Microsatellite Instability High | Phase 2 | Recruiting | Sun Yat-sen University | 105 | 2025-06-01 | 2026-05-22 |
| A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors GSK4418959, PD-1 inhibitor - Neoplasms, Colorectal, Solid Tumor | Phase 1 / Phase 2 | Active not recruiting | GlaxoSmithKline | 14 | 2024-12-13 | 2026-02-02 |
| PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer Sintilimab or Pembrolizumab and medroxyprogesterone acetate (MPA)/ megestrol acetate (MA) - Endometrial Cancer, Endometrioid Carcinoma | Not applicable | Recruiting | Peking University People's Hospital | 10 | 2024-09-02 | 2026-08-10 |
| A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy Alintegimod, Ipilimumab, Nivolumab - Advanced Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | 7 Hills Pharma, LLC | 126 | 2024-08-23 | 2026-04-13 |
| SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr) Dostarlimab-Gxly 50 MG/1 ML Intravenous Solution [JEMPERLI] - Endometrial Cancer Stage I, Mmr Deficiency | Phase 2 | Recruiting | Queensland Centre for Gynaecological Cancer | 10 | 2024-08-01 | 2024-12-03 |
| 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors 177Lu-RAD204 - PDL1 Gene Mutation, Non Small Cell Lung Cancer | Early Phase 1 | Recruiting | Radiopharm Theranostics, Ltd | 30 | 2024-06-03 | 2026-11-02 |
| Familial Adenomatous Poliposys Italian Network (Rete Italiana Poliposi Adenomatosa Familiare) Familial Adenomatous Polyposis (FAP), Attenuated Familial Adenomatous Polyposis (AFAP) | Active not recruiting | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 1500 | 2024-05-13 | 2026-03-10 |
Showing 20 of 60. Sign in to see all of them.
Colorectal Neoplasms (25) · Endometrial Neoplasms (12) · Melanoma (11) · Carcinoma, Non-Small-Cell Lung (10) · Colorectal Neoplasms, Hereditary Nonpolyposis (10) · Carcinoma, Renal Cell (8) · Carcinoma, Hepatocellular (7) · Microsatellite Instability (7) · Neoplasm Metastasis (7) · Carcinoma, Transitional Cell (6) · Colonic Neoplasms (6) · Squamous Cell Carcinoma of Head and Neck (6) · Stomach Neoplasms (6) · Rectal Neoplasms (5)
Neoplasms by Site (52) · Neoplasms (50) · Digestive System Diseases (43) · Gastrointestinal Diseases (43) · Digestive System Neoplasms (42) · Gastrointestinal Neoplasms (41) · Intestinal Diseases (39) · Intestinal Neoplasms (38) · Colonic Diseases (35) · Rectal Diseases (30) · Urogenital Diseases (24) · Urogenital Neoplasms (24) · Female Urogenital Diseases (22) · Female Urogenital Diseases and Pregnancy Complications (22) · Neoplasms by Histologic Type (22)
pembrolizumab (10) · Nivolumab (9) · Ipilimumab (4) · Neoadjuvant Therapy (3) · avelumab (3) · toripalimab (3) · Celecoxib (2) · Immune Checkpoint Inhibitors (2) · Oxaliplatin (2) · Specimen Handling (2) · atezolizumab (2) · durvalumab (2) · sintilimab (2) · ALT-803 (1) · Bevacizumab (1)
National Cancer Institute (NCI) (4) · Sun Yat-sen University (4) · Shanghai Zhongshan Hospital (3) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (2) · GlaxoSmithKline (2) · Incyte Corporation (2) · San Raffaele University (2) · 7 Hills Pharma, LLC (1) · AIO-Studien-gGmbH (1) · Alexander B Olawaiye, MD (1) · Apollomics (Australia) Pty. Ltd. (1) · Asan Medical Center (1) · Austrian Breast & Colorectal Cancer Study Group (1) · D. E. Shaw Research, LLC (1) · Eikon Therapeutics (1)
United States (31) · China (12) · France (8) · Italy (8) · Australia (7) · Canada (7) · Spain (7) · South Korea (5) · Belgium (4) · Germany (4) · Japan (3) · Netherlands (3) · Norway (3) · United Kingdom (3) · Austria (2)
Giulia Martina Cavestro, MD, PhD (2) · Admasu Mamuye, MD (1) · Alexander Olawaiye, MD (1) · Andreas Obermair, Professor (1) · Arash Yavari, MBBS (1) · Chrystelle Colas, Oncogeneticist (1) · Daniel A Morgenstern (1) · Daniel A Morgenstern, MB BChir PhD (1) · David S Hong (1) · Dung Le, MD (1) · Eav Lim, DO (1) · Eugene I Hwang (1) · Falk Roeder, Prof, MD (1) · Floor Backes, MD (1) · Gudrun Piringer, MD, MSc (1)
PMID 31399043, PMID 31765263, PMID 33535600, PMID 34606846, PMID 34688374, PMID 34965951, PMID 34998048, PMID 35235414, PMID 35352512, PMID 37409565, PMID 38022532, PMID 38453598, PMID 39886125, PMID 39955187, PMID 40042547, PMID 40204996, PMID 40579407, PMID 40627813, PMID 42385761
2016 (2), 2023 (2), 2025 (1), P30CA015704 (1), P30CA046934 (1), P50CA062924 (1), U10CA180820 (1), U24CA196172 (1), UM1CA081457 (1), UM1CA154967 (1)